Janknegt R, van der Kuy A, Declerck G, Idzikowski C
Maasland Ziekenhuis, Department of Clinical Pharmacy and Toxicology, Sittard, The Netherlands.
Pharmacoeconomics. 1996 Aug;10(2):152-63. doi: 10.2165/00019053-199610020-00007.
Selection of hypnotics for drug formularies in The Netherlands, France and the UK is made by means of the System of Objectified Judgement Analysis (SOJA) method. The following criteria are included in the method: clinical efficacy (maximal 300 points), adverse effects (250 points), clinical documentation (150 points), cost (120 points), pharmacokinetic properties (80 points), toxicity (50 points), drug interactions (30 points) and the number of tablet strengths available (20 points). In all 3 countries, zolpidem, zopiclone and temazepam showed the highest score, followed by lormetazepam. High scores favour inclusion in formularies. Nitrazepam and loprazolam scored 75 to 130 points less than the top 3, and flunitrazepam shows the lowest score (119 to 183 points less than zolpidem, zopiclone and temazepam). Therefore, the first 3 (or 4) hypnotics are most suitable for formulary inclusion while the others are not.
荷兰、法国和英国通过客观判断分析系统（SOJA）方法来选择用于药品处方集的催眠药。该方法包含以下标准：临床疗效（最高300分）、不良反应（250分）、临床文献（150分）、成本（120分）、药代动力学特性（80分）、毒性（50分）、药物相互作用（30分）以及可用片剂规格数量（20分）。在这三个国家中，唑吡坦、佐匹克隆和替马西泮得分最高，其次是氯美扎酮。高分有利于被纳入处方集。硝西泮和氯普唑仑的得分比排名前三的药物低75至130分，而氟硝西泮得分最低（比唑吡坦、佐匹克隆和替马西泮低119至183分）。因此，前三种（或四种）催眠药最适合被纳入处方集，而其他药物则不适合。
